IBD Subclassification
Inflammatory Bowel Disease
ResearchActive
Key Facts
About Bio-Me
Bio-Me is a commercial-stage microbiome analytics company based in Oslo, Norway. Its proprietary qPCR-based PMP™ platform addresses key limitations of next-generation sequencing (NGS) by offering faster turnaround, higher precision, lower cost, and simplified bioinformatics, making large-scale, routine microbiome analysis feasible. The company has successfully transitioned from a service provider to a diagnostics development partner, with active programs in women's health, oncology, and inflammatory diseases, supported by strategic partnerships with biotechs and participation in EU consortia. Leadership has recently been bolstered with a Co-CEO structure to drive capitalization and commercial growth.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Entyvio (vedolizumab) | Takeda Pharmaceutical | Commercial |
| Function-based Consortium for IBD | PharmaBiome | Pre-clinical |
| Galapagos Collaboration | Scipher Medicine | Discovery/Pre-clinical |
| TEV-‘574 (TL1A Inhibitor) | Teva | Phase 3 |
| Anti-iRhom2 antibodies | SciRhom | Pre-clinical |
| IBD Multi-omics Dataset | Ovation.io | Commercial |